Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | Director | May 11, 2026 | May 14, 2026 |
| Avid Bioservices, Inc.CDMO · Entity 83494 | Director | December 14, 2020 | December 16, 2020 |
| LIFECORE BIOMEDICAL, INC. \DE\LNDC · Entity 6447 | Director | June 04, 2021 | June 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date May 11, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,432 |
Ending reported balance
After 2026-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-11 · Sale · Disposed 3,973 · Balance 48,432 Row 2 · 2026-05-13 · Sale · Disposed 10,000 · Balance 38,432 |
Avid Bioservices, Inc.
Report date December 14, 2020 · Filed December 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.72 · Expires 2027-12-14 | Direct | 124,305 |
Reported balance
After 2020-12-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-14 · Grant · Acquired 10,030 · Balance 124,305 F1: Annual grant of equity awards pursuant to the Issuer's non-employee director compensation program. F2: 100% of each equity award granted to the reporting person shall vest on December 14, 2021. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,379 |
Reported balance
After 2020-12-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-14 · Grant · Acquired 2,379 · Balance 2,379 F3: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's Common Stock. F1: Annual grant of equity awards pursuant to the Issuer's non-employee director compensation program. F2: 100% of each equity award granted to the reporting person shall vest on December 14, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual grant of equity awards pursuant to the Issuer's non-employee director compensation program.
F2: 100% of each equity award granted to the reporting person shall vest on December 14, 2021.
F3: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's Common Stock.
LIFECORE BIOMEDICAL, INC. \DE\
Report date June 04, 2021 · Filed June 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 7,059 |
Reported balance
After 2021-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-04 · Grant · Acquired 7,059 · Balance 7,059 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.
F2: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2026 Filed May 14, 2026 00:22 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 10,000 | $80.63 | $806,300.00 |
DisclosureSEC source: 0001720568-26-000005 · wk-form4_1778718127.xml · nonDerivative · entry 2 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,432 Read SEC document |
| May 11, 2026 Filed May 14, 2026 00:22 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 3,973 | $80.75 | $320,819.75 |
DisclosureSEC source: 0001720568-26-000005 · wk-form4_1778718127.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,432 Read SEC document |
| March 03, 2026 Filed Mar 3, 2026 23:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 6,000 | $74.23 | $445,380.00 |
DisclosureSEC source: 0001720568-26-000002 · wk-form4_1772578861.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,405 Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 23:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001720568-25-000007 · wk-form4_1763420495.xml · nonDerivative · entry 2 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,405 F2 · kind: This transaction reported on this Form 4 reflects a bona fide gift of Company's common stock to a donor-advised fund ("DAF") for charitable purposes. The Reporting Person retains no beneficial ownership or control over the donated securities following the contribution. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 23:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 8,643 | $86.88 | $750,903.84 |
DisclosureSEC source: 0001720568-25-000007 · wk-form4_1763420495.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,405 F1 · price: The shares were sold in multiple trades at prices ranging from $86.15 to $87.80. The price reported above reflects the weighted average sales price. Read SEC document |
| August 15, 2025 Filed Aug 18, 2025 20:34 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 9,000 | $89.05 | $801,450.00 |
DisclosureSEC source: 0001720568-25-000004 · wk-form4_1755549267.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,048 Read SEC document |
| May 22, 2025 Filed May 27, 2025 22:15 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 4,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001720568-25-000002 · wk-form4_1748384127.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,048 F1 · kind: Represents a restricted stock award that will vest in full on May 22, 2026. Read SEC document |
| May 21, 2024 Filed May 24, 2024 00:03 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 4,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001720568-24-000003 · wk-form4_1716509024.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,712 F1 · kind: Represents a restricted stock award that will vest in full on May 21, 2025. Read SEC document |
| May 23, 2023 Filed May 24, 2023 20:34 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 6,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064158 · tm2316872-5_4seq1.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,302 F1 · kind: Represents a restricted stock award that will vest in full on May 23, 2024. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 22:24 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 10,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004393 · form4-04292022_030412.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,437 F1 · kind: Represents a restricted stock award that will vest in full on April 27, 2023. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 21:39 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | PurchaseCommon Stock | 5,000 | $27.76 | $138,794.00 |
DisclosureSEC source: 0001415889-22-003268 · form4-03222022_020356.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,388 F1 · price: The shares were acquired in multiple trades at prices ranging from $27.475 to $27.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:06 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantRestricted Stock Unit · Derivative | 7,059 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-21-001574 · primary_01.xml · derivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,059 Underlying: Common Stock · 7,059 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 20:10 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | PurchaseCommon Stock | 10,000 | $11.26 | $112,600.00 |
DisclosureSEC source: 0001593968-21-001158 · primary_01.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 20:34 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 9,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001653 · form4-03252021_010333.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,388 F1 · kind: Represents a restricted stock award that will vest in full on March 23, 2022. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 23:55 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | PurchaseCommon Stock | 4,000 | $32.89 | $131,555.20 |
DisclosureSEC source: 0001415889-21-001560 · form4-03172021_040314.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,096 F1 · price: The shares were acquired in multiple trades at prices ranging from $32.645 to $33.2699. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 20:00 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantRestricted Stock Units · Derivative | 2,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-20-004319 · ownership.xml · derivative · entry 2 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,379 Underlying: Common Stock · 2,379 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's Common Stock. F1 · shares: Annual grant of equity awards pursuant to the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: 100% of each equity award granted to the reporting person shall vest on December 14, 2021. F2 · derivative.expiration_date: 100% of each equity award granted to the reporting person shall vest on December 14, 2021. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 20:00 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantStock Option (right to buy) · Derivative | 10,030 | $0.00 Strike: $10.72 | $0.00 |
DisclosureSEC source: 0001683168-20-004319 · ownership.xml · derivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,305 Underlying: Common Stock · 10,030 shares Expires 2027-12-14 F1 · shares: Annual grant of equity awards pursuant to the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: 100% of each equity award granted to the reporting person shall vest on December 14, 2021. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:11 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | PurchaseCommon Stock | 5,000 | $25.96 | $129,800.00 |
DisclosureSEC source: 0001415889-20-002608 · form4-11122020_021137.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,096 Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:15 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantRestricted Stock Unit · Derivative | 5,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-20-002054 · primary_01.xml · derivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,398 Underlying: Common Stock · 5,398 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:18 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | PurchaseCommon Stock | 3,000 | $30.89 | $92,670.00 |
DisclosureSEC source: 0001415889-20-002087 · form4-08122020_010803.xml · nonDerivative · entry 3 Walsh Patrick D · CIK 0001720568 · Director · CHAIRMAN, INTERIM PRES. & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,096 Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:18 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | PurchaseCommon Stock | 4,000 | $30.98 | $123,920.00 |
DisclosureSEC source: 0001415889-20-002087 · form4-08122020_010803.xml · nonDerivative · entry 2 Walsh Patrick D · CIK 0001720568 · Director · CHAIRMAN, INTERIM PRES. & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,096 Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:18 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | PurchaseCommon Stock | 3,000 | $30.40 | $91,200.00 |
DisclosureSEC source: 0001415889-20-002087 · form4-08122020_010803.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director · CHAIRMAN, INTERIM PRES. & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,096 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:31 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 7,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-060890 · tm2019363d1_4.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director · Interim President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,096 F1 · kind: The restricted stock was granted to the Reporting Person in connection with his commencement as interim President and Chief Executive Officer of the issuer. The restricted stock vests on the earlier of (i) May 11, 2021 or (ii) the termination of the Reporting Person's service as interim President and Chief Executive Officer, except in connection with a "for cause" termination. Read SEC document |
| April 10, 2020 Filed Apr 14, 2020 20:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 9,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-046395 · tm2015775d4_form4.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,046 F1 · kind: The restricted stock vests on April 10, 2021. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 13:09 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | PurchaseCommon Stock, $0.001 par value | 30,000 | $3.22 | $96,600.00 |
DisclosureSEC source: 0001683168-20-000942 · ownership.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Diligence Team LLC Pension Account Disclosed balance after: 30,000 F1 · price: The price reported for this transaction is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.15 to $3.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 20:36 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantStock Option (right to buy) · Derivative | 19,675 | $0.00 Strike: $6.87 | $0.00 |
DisclosureSEC source: 0001683168-20-000109 · ownership.xml · derivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,275 Underlying: Common Stock · 19,675 shares Expires 2027-01-09 F1 · shares: Annual grant of stock options pursuant to the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: This option fully vests one year from the date of grant. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 20:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Options · Derivative | 2,409 | $0.00 Strike: $66.39 | $0.00 |
DisclosureSEC source: 0001144204-19-017416 · tv517663_4.xml · derivative · entry 2 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,409 Underlying: Common Stock · 2,409 shares Expires 2029-03-27 F1 · security: The restricted stock and stock options vest on March 28, 2020. F1 · derivative.exercise_date: The restricted stock and stock options vest on March 28, 2020. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 20:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 1,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-017416 · tv517663_4.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,791 F1 · security: The restricted stock and stock options vest on March 28, 2020. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 20:26 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantStock Option (right to buy) · Derivative | 19,600 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001683168-18-003748 · ownership.xml · derivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,600 Underlying: Common Stock · 19,600 shares Expires 2025-12-14 F1 · derivative.exercise_date: This option fully vests one year from the date of grant. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Options · Derivative | 2,225 | $0.00 Strike: $65.86 | $0.00 |
DisclosureSEC source: 0001144204-18-033532 · tv496176_4.xml · derivative · entry 2 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,225 Underlying: Common Stock · 2,225 shares Expires 2028-06-05 F1 · security: The restricted stock and stock options are subject to vesting, and 50% of the restricted stock and stock options vest on May 17, 2019, and the remaining 50% of the restricted stock and stock options vest on May 17, 2020. F1 · derivative.exercise_date: The restricted stock and stock options are subject to vesting, and 50% of the restricted stock and stock options vest on May 17, 2019, and the remaining 50% of the restricted stock and stock options vest on May 17, 2020. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-033532 · tv496176_4.xml · nonDerivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 F1 · security: The restricted stock and stock options are subject to vesting, and 50% of the restricted stock and stock options vest on May 17, 2019, and the remaining 50% of the restricted stock and stock options vest on May 17, 2020. Read SEC document |
| October 20, 2017 Filed Oct 24, 2017 17:23 UTC | Avid Bioservices, Inc. PPHM · Entity 83494 | GrantStock Options (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001683168-17-002736 · walsh_f4.xml · derivative · entry 1 Walsh Patrick D · CIK 0001720568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-10-20 F1 · derivative.exercise_date: This option vests in thirty-six (36) equal monthly installments over a three (3) year period beginning November 20, 2017 and each month thereafter until fully-vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.